CareDx, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
CareDx completed sale of Lab Products business (IVD PCR/NGS kits) to Eurobio Scientific for $171.2M cash on June 30, 2026, and completed acquisition of Naveris (NavDx HPV-cancer MRD test generating ~$35M 2025 revenue) in Q3 2026. Together, these transactions pivot the company from global diagnostics toward U.S. precision medicine in transplant and specialty oncology, expanding addressable market to >$12B.
Why this rating
~$171M proceeds (17% of market cap) plus $35M+ oncology revenue is material. Strategic pivot to high-growth oncology meaningful; exe risk on integration and market traction real.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.